Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.jvca.2016.09.030 | DOI Listing |
Int J Cardiovasc Imaging
January 2025
Cardiology, Endeavor NorthShore Cardiovascular Institute, Evanston, IL, USA.
This study aims to evaluate the implementation of concomitant CAD assessment on pre-TAVI (transcatheter aortic valve implantation) planning CTA (CT angiography) aided by CT-FFR (CT-fractional flow reserve) [The CT2TAVI protocol] and investigates the incremental value of CT-FFR to coronary CT angiography (CCTA) alone in the evaluation of patients undergoing CT2TAVI. This is a prospective observational real-world cohort study at an academic health system on consecutive patients who underwent CTA for TAVI planning from 1/2021 to 6/2022. This represented a transition period in our health system, from not formally reporting CAD on pre-TAVI planning CTA (Group A) to routinely reporting CAD on pre-TAVI CTA (Group B; CT2TAVI protocol).
View Article and Find Full Text PDFAm J Case Rep
January 2025
Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
BACKGROUND Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure increasingly used to treat severe aortic stenosis, especially in elderly patients and those with significant comorbidities who are at high risk for surgical intervention. While TAVR is generally safe and effective, rare complications can occur, including cerebral air embolism, which can result in acute neurological deficits. This report presents the case of a 75-year-old man who developed a cerebral air embolism following TAVR.
View Article and Find Full Text PDFJACC Cardiovasc Interv
January 2025
Ascension St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.
Background: The optimal timing for percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) is debatable.
Objectives: The aim of this study was to compare outcomes based on the timing of PCI in stable coronary artery disease patients undergoing TAVR.
Methods: Leveraging the STS/ACC TVT Registry and Medicare Linkage, we analyzed patients with stable coronary artery disease undergoing PCI and TAVR between 2015 and 2023 using the SAPIEN 3 balloon-expandable valve platform.
JACC Cardiovasc Interv
January 2025
Institut Cardiovasculaire Paris-Sud, Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France. Electronic address:
Background: The prevalence of coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is high. Treatment of a coronary events (CE) after TAVR can be technically challenging.
Objectives: The authors sought to assess the incidence and prognostic impact of CE after TAVR.
Ann Thorac Surg
January 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.
Transcatheter aortic valve-in-valve replacement presents a viable, minimally invasive approach to replacing degraded bioprosthetic surgical valves. The major drawback of this technique is poor hemodynamics in the form of patient-prosthesis mismatch and high transvalvular gradients. This is commonly attributable to the reduced valvular diameter from the transcatheter heart valve fixed inside the degraded bioprosthesis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!